Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus EGFR Antibody or Chemotherapy in Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
ChiCTR2600119577Phase 4Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: 2-year Overall Survival (OS) Rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600119577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119577.